American Journal of Cardiovascular Drugs

Therapeutic Potential of Aleglitazar, a New Dual PPAR-α/γ Agonist: Implications for Cardiovascular Disease in Patients with Diabetes Mellitus
pp. 209-216(8)
Authors: Cavender, Matthew A.; Lincoff, A. Michael

Platelet P2Y₁₂ Receptor Inhibition: An Update on Clinical Drug Development
pp. 217-226(10)
Authors: Vivas, David; Angiolillo, Dominick J.

Contrast Agents Used in Cardiovascular Magnetic Resonance Imaging: Current Issues and Future Directions
pp. 227-237(11)
Authors: Moriarty, John M.; Finn, J. Paul; Fonseca, Carissa G.

Effect of an Olmesartan Medoxomil-Based Treatment Algorithm on Systolic Blood Pressure in Patients with Stage 1 or 2 Hypertension: A Randomized, Double-Blind, Placebo-Controlled Study
pp. 239-246(8)
Authors: Kereiakes, Dean J.; Maa, Jen-Fue; Shojaee, Ali; Dubiel, Robert

β-Blockers Reduce Mortality in Patients Undergoing High-Risk Non-Cardiac Surgery
pp. 247-259(13)
Authors: Angeli, Fabio; Verdecchia, Paolo; Karthikeyan, Ganesan; Mazzotta, Giovanni; Gentile, Giorgio; Reboldi, Gianpaolo

Retrospective Review of Digoxin Exposures to a Poison Control System following Recall of Digitek® Tablets
pp. 261-263(3)
Authors: >Sean Patrick Nordt,; Minns, Alicia; Tomaszewski, Christian; Cantrell, F. Lee; Clark, Richard F.

Trimetazidine Activates Paraoxonase: A Non-Randomized, Observational, Retrospective Study
pp. 265-266(2)
Authors: >Goran Pante Koracevic,; Cvetkovic, Tatjana; Koracevic, Maja

Anacetrapib
pp. 267-270(4)

Mipomersen
pp. 271-279(9)